Parkinson Hastalığı Tedavisi
Özet
Parkinson hastalığı, dopaminerjik nöron kaybı ve Lewy cisimcikleri ile karakterize, motor ve motor dışı semptomların birlikte görüldüğü kronik ve ilerleyici bir nörodejeneratif hastalıktır. Bu bölümde Parkinson hastalığının güncel tedavi yaklaşımları, klinik pratikle uyumlu ve bütüncül bir bakış açısıyla ele alınmıştır. Levodopa başta olmak üzere dopaminerjik tedaviler, dopamin agonistleri, MAO-B ve COMT inhibitörleri gibi farmakolojik seçenekler; hastalığın evresi, hasta yaşı ve eşlik eden klinik özellikler doğrultusunda değerlendirilmiştir. Motor dalgalanmalar ve diskinezilerin yönetiminde kombinasyon tedavileri ve ileri evre hastalarda uygulanan cihaz destekli yaklaşımlar ayrıntılı olarak sunulmuştur. Ayrıca depresyon, psikoz, bilişsel bozukluk, uyku problemleri ve otonomik disfonksiyonlar gibi motor dışı semptomların tedavisi güncel kanıtlar ışığında tartışılmıştır. Son bölümde gen tedavisi, kök hücre uygulamaları, immünoterapi ve dijital sağlık teknolojileri gibi geleceğe yönelik tedavi stratejilerine yer verilmiştir. Bu bölüm, Parkinson hastalığının tedavisinde kişiselleştirilmiş ve multidisipliner yaklaşımın önemini vurgulamayı amaçlamaktadır.
Referanslar
Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. *Nature Reviews Disease Primers.* 2017;3:17013. doi:10.1038/nrdp.2017.13
Kalia LV, Lang AE. Parkinson’s disease. *The Lancet.* 2015;386(9996):896–912. doi:10.1016/S0140-6736(14)61393-3
Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. *Nature Reviews Neuroscience.* 2017;18(2):101–113. doi:10.1038/nrn.2016.178
Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease. *Nature Reviews Neurology.* 2019;15(10):565–581. doi:10.1038/s41582-019-0244-7
Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. *Movement Disorders.* 2015;30(12):1600–1611. doi:10.1002/mds.26431
Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson’s disease: progress and therapeutic implications. *Movement Disorders.* 2013;28(1):14–23. doi:10.1002/mds.25249
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. *Movement Disorders.* 2015;30(12):1591–1601. doi:10.1002/mds.26424
Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. *Movement Disorders.* 2018;33(8):1248–1266. doi:10.1002/mds.27372
Katzenschlager R, Lees AJ. Treatment of Parkinson’s disease: levodopa as the first choice. *Journal of Neurology.* 2002;249(Suppl 2):II19–II24. doi:10.1007/s00415-002-1204-4
Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. *Neurology.* 2009;72(21 Suppl 4):S1–S136. doi:10.1212/WNL.0b013e3181a1d44c
Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. *Movement Disorders.* 2005;20(Suppl 11):S11–S16. doi:10.1002/mds.20458
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. *Movement Disorders.* 2001;16(3):448–458. doi:10.1002/mds.1090
Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. *The Lancet Neurology.* 2010;9(6):573–580. doi:10.1016/S1474-4422(10)70106-X
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. *The New England Journal of Medicine.* 2000;342(20):1484–1491. doi:10.1056/NEJM200005183422004
Torti M, Bravi D, Vacca L, et al. Are all dopamine agonists essentially the same? *Drugs.* 2019;79:693–703. doi:10.1007/s40265-019-01103-2
Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. *Neurology.* 2006;67(7):1254–1257. doi:10.1212/01.wnl.0000238503.20816.13
Stocchi F, Rascol O, Poewe W, Chaudhuri KR, Kassubek J, Lopez Manzanares L, et al. Apomorphine sublingual film compared with subcutaneous apomorphine for OFF episodes in Parkinson’s disease: an open-label, randomized, crossover study. *Journal of Parkinson’s Disease.* 2023;13(8):1329–1342. doi:10.3233/JPD-230072
Stocchi F, Borgohain R, Onofrj M, et al. A randomized, double-blind, placebo-controlled trial of safinamide in levodopa-treated patients with Parkinson disease and motor fluctuations. *Clinical Neuropharmacology.* 2012;35(5):185–192. doi:10.1097/WNF.0b013e31825d2b67
Schapira AH, Fox SH, Hauser RA, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. *JAMA Neurology.* 2017;74(2):216–224. doi:10.1001/jamaneurol.2016.4467
Stocchi F, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. *Movement Disorders.* 2012;27(1):106–112.
Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. *Pharmacotherapy.* 2007;27(12 Pt 2):174S–185S. doi:10.1592/phco.27.12part2.174S
Lees AJ, Ferreira J, Rascol O, et al. Opicapone as an adjunct to levodopa therapy in Parkinson’s disease. *The Lancet Neurology.* 2017;16(7):575–584. doi:10.1016/S1474-4422(17)30145-5
Abdel-Salam OM. Drugs used to treat Parkinson’s disease, present status and future directions. *CNS & Neurological Disorders - Drug Targets.* 2008;7(4):321–342.
Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. *Journal of Neurology, Neurosurgery & Psychiatry.* 2004;75(1):141–143.
Fox SH, Katzenschlager R, Lim SY, et al. Update on Treatments for Parkinson’s Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review. *Movement Disorders.* 2023;38(6):925–940. doi:10.1002/mds.29468
Antonini A, Chaudhuri KR, Poewe W, et al. Device-aided therapies in Parkinson’s disease: clinical perspectives and practical recommendations. *Parkinsonism & Related Disorders.* 2021;82(Suppl 1):S63–S70. doi:10.1016/j.parkreldis.2020.12.027
Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. *The Lancet Neurology.* 2006;5(3):235–245. doi:10.1016/S1474-4422(06)70373-8
Aarsland D, Kramberger MG. Neuropsychiatric symptoms in Parkinson’s disease. *Journal of Parkinson’s Disease.* 2015;5(3):659–667. doi:10.3233/JPD-150557
Ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. *Nature Reviews Neurology.* 2017;13(2):81–95. doi:10.1038/nrneurol.2016.200
Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. *JAMA.* 2020;323(6):548–560. doi:10.1001/jama.2019.22360
Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. *Movement Disorders.* 2011;26(3):399–406. doi:10.1002/mds.23462
Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. *The New England Journal of Medicine.* 2004;351(24):2509–2518. doi:10.1056/NEJMoa041470
Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). *Journal of Clinical Sleep Medicine.* 2010;6(1):85–95.
Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Droxidopa in neurogenic orthostatic hypotension. *Clinical Autonomic Research.* 2021;31(1):3–13. doi:10.1007/s10286-020-00747-9
Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. *Clinical Autonomic Research.* 2011;21(2):69–72. doi:10.1007/s10286-011-0119-5
Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. *Neurobiology of Disease.* 2012;46(3):559–564. doi:10.1016/j.nbd.2011.10.014
Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. *Movement Disorders.* 2006;21(6):737–745. doi:10.1002/mds.20867
Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. *The New England Journal of Medicine.* 2006;355(9):896–908. doi:10.1056/NEJMoa060281
Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson’s disease with deep brain stimulation. *The Lancet Neurology.* 2012;11(5):429–442. doi:10.1016/S1474-4422(12)70049-2
Antonini A, Yegin A, Preda C, et al. Global long-term study on LCIG in advanced Parkinson’s disease. *Movement Disorders.* 2016;31(4):538–546. doi:10.1002/mds.26443
Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa–carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. *The Lancet Neurology.* 2014;13(2):141–149. doi:10.1016/S1474-4422(13)70293-X
Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. *Neurology.* 2019;92(16):e1894–e1903. doi:10.1212/WNL.0000000000007314
LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson’s disease. *The Lancet Neurology.* 2011;10(4):309–319. doi:10.1016/S1474-4422(11)70019-6
Takahashi J. iPS cell-based therapy for Parkinson’s disease: a prospective. *Brain and Nerve.* 2021;73(5):487–493. doi:10.11477/mf.1416201961
Barker RA, Parmar M, Studer L, Takahashi J. Human trials of stem cell-derived dopamine neurons for Parkinson’s disease: dawn of a new era. *Cell Stem Cell.* 2017;21(5):569–573. doi:10.1016/j.stem.2017.09.014
Pagano G, Taylor KI, Anzures-Cabrera J, et al. Trial of prasinezumab in early-stage Parkinson’s disease. *The New England Journal of Medicine.* 2022;387(5):421–432. doi:10.1056/NEJMoa2202864
Mullin S, Schapira AH. α-Synuclein immunotherapy for Parkinson’s disease: recent advances. *Expert Opinion on Biological Therapy.* 2021;21(5):589–597. doi:10.1080/14712598.2021.1890636
Espay AJ, Bonato P, Nahab FB, et al. Technology in Parkinson’s disease: challenges and opportunities. *NPJ Digital Medicine.* 2020;3:101. doi:10.1038/s41746-020-00329-8
Lipsmeier F, Taylor KI, Kilchenmann T, et al. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson’s disease trial. *Movement Disorders.* 2018;33(8):1287–1297. doi:10.1002/mds.27376
